Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
ADA 2020 – Medtronic leads Insulet, but things could change
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
Collaborative diabetes tech on the Horizon
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Approvals of high-risk devices drop as de novos take off
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
The fourth quarter sell-off hurt big medtech less than big pharma
Some medtech stocks did decline in 2018, but many more increased in value.
Ascensia banks on accuracy and collaboration to face down new tech
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
